« Return to News | R&D Trends

Ensemble Therapeutics, Novartis collaborate

Wednesday, August 7, 2013 11:51 AM

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, has initiated a two-part R&D collaboration with Novartis. The companies have entered into a strategic development agreement for Ensemble's most advanced proprietary program that targets the inflammatory cytokine IL-17, and for a new program to discover novel small molecule treatments against undisclosed drug targets specified by Novartis using Ensemble's proprietary drug discovery platforms.

Ensemble will receive an upfront payment from Novartis and is also eligible to receive potential success-based development and sales milestone payments. In addition, Ensemble will receive tiered royalties on potential future sales of products that may arise from the collaboration. Novartis will also provide research funding to Ensemble during the term of the collaboration.

Ensemble's class of IL-17 antagonists, licensed by Novartis, represent the potential for first-in-class, orally active, small molecule inhibitors of the clinically-validated target. The protein-protein nature of interaction of IL-17 with its receptor has made design of traditional small molecule pharmaceutical inhibitor difficult, so has been addressed to date with injectable protein therapeutics directed to the ligand. An orally-active inhibitor of IL-17 would have a profile complementary to the current class of clinical stage anti-IL-17 antibody products, which have shown compelling efficacy in multiple human clinical trials involving various inflammatory and autoimmune diseases.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.